Table 2.
Characteristics associated with methamphetamine use at baseline and/or 12 month follow up, Together 5,000 cohort study, n = 4786, 2017 – 2019
| Abstinent: No use at BL or 12M n = 4127, 86.2% |
Baseline only: BL use only, no use between BL and 12M n = 143, 3.0% |
Incident use: Indicated use between BL and 12M n = 94, 2.0% |
Persistent use: Baseline and 12M use n = 422, 8.8% |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Frequency | (%) | Frequency | (%) | Frequency | (%) | Frequency | (%) | Chi-squared | p | |
| Age at enrollment | 134.90 | <.0001 | ||||||||
| 16–24 years old | 1010 | (92.2) | 26 | (2.4) | 30 | (2.7) | 30 | (2.7) | ||
| 25–35 years old | 2081 | (85.7) | 91 | (3.8) | 45 | (1.9) | 212 | (8.7) | ||
| 36–45 years old | 797 | (80.3) | 20 | (2.0) | 18 | (1.8) | 157 | (15.8) | ||
| 46–55 years old | 239 | (88.9) | 6 | (2.2) | 1 | (0.4) | 23 | (8.6) | ||
| Gender | 10.37 | 0.02 | ||||||||
| Male | 4029 | (86.3) | 135 | (2.9) | 89 | (1.9) | 417 | (8.9) | ||
| Gender minority | 98 | (84.5) | 8 | (6.9) | 5 | (4.3) | 5 | (4.3) | ||
| Race/ethnicity | 44.72 | <.0001 | ||||||||
| White | 2202 | (85.8) | 64 | (2.5) | 43 | (1.7) | 259 | (10.1) | ||
| Black | 438 | (90.7) | 14 | (2.9) | 12 | (2.5) | 19 | (3.9) | ||
| Latinx | 965 | (85.0) | 48 | (4.2) | 27 | (2.4) | 96 | (8.5) | ||
| API | 171 | (93.4) | 3 | (1.6) | 3 | (1.6) | 6 | (3.3) | ||
| All Other, Multiracial | 351 | (84.4) | 14 | (3.4) | 9 | (2.2) | 42 | (10.1) | ||
| Incident HIV at 12 months (HIV diagnoses between BL and 12M) | 75.74 | <.0001 | ||||||||
| No | 4064 | (87.0) | 138 | (3.0) | 88 | (1.9) | 381 | (8.2) | ||
| Yes | 63 | (54.8) | 5 | (4.4) | 6 | (5.2) | 41 | (35.7) | ||
| Prevalent HIV (baseline and 12 months) | 183.40 | <.0001 | ||||||||
| No | 3876 | (88.4) | 116 | (2.6) | 87 | (2.0) | 308 | (7.0) | ||
| Yes | 138 | (55.0) | 18 | (7.2) | 6 | (2.4) | 89 | (35.5) | ||
| Indeterminate | 38 | (79.2) | 3 | (6.3) | 0 | (0.0) | 7 | (14.6) | ||
| Syphilis | 122.06 | <.0001 | ||||||||
| No diagnoses (lifetime) | 3786 | (88.1) | 116 | (2.7) | 84 | (2.0) | 314 | (7.3) | ||
| In the year prior to enrollment | 120 | (76.9) | 8 | (5.1) | 1 | (0.6) | 27 | (17.3) | ||
| Incident: Diagnosis between enrollment and 12 months | 185 | (69.6) | 16 | (6.0) | 8 | (3.0) | 57 | (21.4) | ||
| Persistent: In the year prior to enrollment as well as following enrollment | 36 | (56.3) | 3 | (4.7) | 1 | (1.6) | 24 | (37.5) | ||
| Incarceration | 376.85 | <.0001 | ||||||||
| No incarceration in lifetime or during 12 month follow up | 3682 | (90.1) | 93 | (2.3) | 84 | (2.1) | 227 | (5.6) | ||
| Lifetime: Prior to enrollment, but not during 12 month follow up | 365 | (66.7) | 36 | (6.6) | 7 | (1.3) | 139 | (25.4) | ||
| Incident: Incarcerated between enrollment and 12 month | 56 | (76.7) | 4 | (5.5) | 0 | (0.0) | 13 | (17.8) | ||
| Persistent: In the year prior to enrollment as well as following enrollment | 24 | (30.0) | 10 | (12.5) | 3 | (3.8) | 43 | (53.8) | ||
BL: Baseline (reported at BL with a 3 month recall window), 12M: 12 months (reported at month 12 with a 12 month recall window)